TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. reported its consolidated financial results for the nine months ending July 31, 2025, showing net sales of ¥2,818 million and a profit attributable to owners of ¥86 million. The company has shifted to consolidated accounting, making year-on-year comparisons unavailable, but it forecasts full-year net sales of ¥3,774 million and a profit of ¥112 million, indicating a positive outlook for the fiscal year.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry and is listed on the Tokyo Stock Exchange. The company focuses on developing and providing innovative cell-based therapies and regenerative medicine solutions.
Average Trading Volume: 55,295
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen12.13B
See more data about 4880 stock on TipRanks’ Stock Analysis page.